Gilead Sciences, Inc
GILD
NASDAQ
Biotechnology
$138.36
USD
+0.22 (+0.16%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $169.87B
Volume 3.4M
Revenue
$30.46B
TTM
+5.5%
YoY
Gross Margin
80%
TTM
+1.3%
YoY
Net Income
$-3.24B
TTM
-151.3%
YoY
Operating Cash Flow
$13.55B
TTM
+37.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 7,082.0 | 7,769.0 | 7,925.0 | 6,960.0 | 7,803.0 |
YoY Growth | +1.8% | +3.0% | +4.7% | +4.4% | +10.2% |
Cost of Revenue | 1,501.0 | 1,569.0 | 1,624.0 | 1,445.0 | 1,579.0 |
Gross Profit | 5,581.0 | 6,200.0 | 6,301.0 | 5,515.0 | 6,224.0 |
Selling, General & Administrative | 1,365.0 | 1,357.0 | 1,794.0 | 1,451.0 | 1,921.0 |
Other Operating Expenses | 190.0 | 170.0 | 939.0 | 107.0 | 1,750.0 |
Total Operating Expenses | 3,107.0 | 2,873.0 | 4,317.0 | 2,930.0 | 16,618.0 |
Operating Income | 2,474.0 | 3,327.0 | 1,984.0 | 2,585.0 | -10,394.0 |
EBITDA | 3,355.0 | 4,183.0 | 3,610.0 | 3,381.0 | -7,946.0 |
Other Income / Expense | 209.0 | 570.0 | 349.0 | 235.0 | 387.0 |
Total Other Income / Expense | -45.0 | 314.0 | 94.0 | -5.0 | 140.0 |
Income Before Income Taxes | 2,429.0 | 3,641.0 | 2,078.0 | 2,580.0 | -10,254.0 |
Income Taxes | 468.0 | 589.0 | -105.0 | 559.0 | 242.0 |
Net Income | 1,960.0 | 3,052.0 | 2,183.0 | 2,021.0 | -10,496.0 |
Consolidated Net Income / Loss | 1,961.0 | 3,052.0 | 2,183.0 | 2,021.0 | -10,496.0 |
Net Income Attributable to Common Shareholders | 1,960.0 | 3,052.0 | 2,183.0 | 2,021.0 | -10,496.0 |
Basic EPS | $1.57 | $2.46 | $1.76 | $1.63 | -$8.45 |
Diluted EPS | $1.56 | $2.43 | $1.74 | $1.61 | -$8.45 |
Basic Shares Outstanding | 1,245.0M | 1,243.0M | 1,242.0M | 1,242.0M | 1,243.0M |
Diluted Shares Outstanding | 1,255.0M | 1,254.0M | 1,252.0M | 1,254.0M | 1,243.0M |